Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 28, 2016

Primary Completion Date

December 1, 2018

Study Completion Date

May 31, 2020

Conditions
Advanced Solid Tumors
Interventions
DRUG

Tislelizumab

Administered intravenously

Trial Locations (12)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

150000

Harbin Medical University Cancer Hospital, Harbin

200000

Fudan University Shanghai Cancer Center, Shanghai

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

210029

Jiangsu Province Hospital, Nanjing

310009

Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

330006

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

510000

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou

510080

Guangdong Provincial Peoples Hospital, Guangzhou

519000

The Fifth Affiliated Hospital Sun Yat Sen University, Zhuhai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY